Effects of Chemotherapy on Urinary Prostacyclin and Thromboxane in Ovarian Cancer Patients
Author Information
Author(s): A. Aitokallio-Tallberg, L. Viinikka, O. Ylikorkala
Primary Institution: University of Helsinki
Hypothesis
How does chemotherapy affect the urinary excretion of prostacyclin and thromboxane in patients with ovarian cancer?
Conclusion
Ovarian cancer patients excrete more prostacyclin and thromboxane than those with endometriosis, and chemotherapy initially increases but later suppresses their excretion.
Supporting Evidence
- Patients with ovarian cancer had urinary excretion of prostanoids 4.4-5.8 times higher than those with endometriosis.
- Cytostatic treatment led to a 50-120% rise in prostanoid excretion initially.
- After chemotherapy, prostanoid output decreased significantly and remained low for at least 2 weeks.
Takeaway
This study looked at how cancer treatment affects certain substances in the urine of women with ovarian cancer. It found that treatment changes these substances a lot at first, but then they go down after a while.
Methodology
Measured urinary excretion of prostacyclin and thromboxane products using HPLC and radioimmunoassay before, during, and after chemotherapy.
Limitations
Small sample size and lack of long-term follow-up data.
Participant Demographics
Patients aged 15 to 73, with a mix of premenopausal and post-menopausal women.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.0005
Want to read the original?
Access the complete publication on the publisher's website